{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'e.', 'The monitor (or designated representative) is responsible for writing a formal report no more than 10 business', 'days following the visit. This will allow members of the DCC to review reports prior to formal submission to sites.', 'f.', 'The monitoring visit report is sent initially to the DCC, and the study PI.', 'g.', 'The study PI and study statistician will review the monitoring reports and make recommendations to the Site PI', 'and monitor within 2 weeks of receipt.', 'h.', 'It is the responsibility of the CCC to write a letter, and send it along with the report and any recommendations to', 'the site PI of the institution being monitored, outlining any issues resulting from the monitoring visit. This will be', 'done within one week of reviewing the monitoring report.', 'i.', 'If the actions and responses are straightforward with no major concerns, the CCC will send a letter of', 'compliance and recommendation of approval of the monitoring report and response(s)', 'j.', 'The timeline for response will begin with a four week deadline. If further time is needed, the sanctioned', 'institution may request (in writing) an extension and state the reason. If the institution in question is that of the', 'study contact PI, the co-PI will be informed and issue the letter.', '2.', 'The Site PI responsibilities are:', 'a. A reply to all issues addressed in monitoring report is due within 30 days of receipt of the monitoring review.', 'This should be stipulated in the official letter. The letter should be sent via email notification.', 'b. Serious issues may be referred to the DCC for further review. The DCC may decide to inform the DSMB.', 'c.', 'Once a site has responded to the requests in a timely manner, the DCC may either:', 'Send a formal closure letter stating that compliance has been met and close-out the monitoring review and', 'follow-up.', 'Send a formal letter stating that compliance has not been met and the course of action that will follow;', 'options may consist of any or all of the following:', 'Site visit and/or formal monitoring visit', 'Place the site on probation, with agreement of the CCC. The appropriate timeline to correct issues', 'will be determined on a case-by-case basis depending upon the nature of the issue(s).', 'Require further training with a probationary period (to be determined)', 'Obtain recommendations from other groups, i.e., DSMB, sponsor, site IRBs and etc.', 'd.', 'Cases of severe non-compliance will be submitted to the CCC for recommendations that could result in:', 'Probation', 'Funding restrictions', 'A call to cease site enrollment', 'Report filed to the appropriate regulatory entities', 'Rejection of site status', 'Once a site is placed on probation, reinstatement can occur only with a formal letter signed by the study PI. In cases', 'where non-compliance pertains to the institution of the Study PI (K. Saag), then a letter signed by the co-PI (P.', 'Khanna) would be sent.', 'In addition, Drs. David Fox, MD (U. Michigan) and Angelo Gaffo, MD, MPH (UAB) will serve as medical monitors for', 'the study. Drs. Fox and Gaffo will be consulted on an ad hoc to answer questions from clinical investigators at UAB,', 'UM, and from participating clinical sites. Their primary responsibilities include (but are not limited to):', 'Providing medical leadership to sites by answering investigator questions about the protocol and the', 'medical management of subject emergencies', 'Providing input on clinical development plans, protocol design, and risk assessments', 'Reviewing all study team deliverables, such as final narratives and clinical study reports', 'Reviewing and analyzing safety and efficacy trends', '39']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '11.1.8 QUALITY ASSURANCE AND QUALITY CONTROL', 'Quality control (QC) procedures have been implemented beginning with the eDES data entry system and data QC checks', 'that will be run on the database once enrollment begins. Any missing data or data anomalies will be communicated to', 'the site(s) for clarification/resolution.', '11.1.9 DATA HANDLING AND RECORD KEEPING', '11.1.9.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES', 'Data collection will be the responsibility of the clinical trial staff at the site under the supervision of the site investigator.', 'The investigator will be responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data', 'reported. All hardcopy source documents will be completed in a neat, legible manner to ensure accurate interpretation', 'of data. Hardcopies of the study visit worksheets will be provided for use as source document worksheets for recording', 'data for each participant enrolled in the study. Data recorded in the eCRF derived from source documents will be', 'consistent with the data recorded on the source documents.', 'Clinical data (including adverse events (AEs), concomitant medications) and clinical laboratory data will be entered into', 'EDES, a 21 CFR Part 11-compliant data capture system provided by the Data Coordinating Center at the UAB School of', 'Public Health. The eDES data system includes password protection and internal quality checks, such as automatic range', 'checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from', 'the source documents. Printed laboratory reports and reports from the electronic medical record must include the date', 'printed and signed by staff member printing the report.', 'As part of participating in a NIH-sponsored or NIH-affiliated study, each site will permit authorized representatives of the', 'NIH, sponsor, and regulatory agencies to examine (and when permitted by applicable law, to copy) clinical records for', 'the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress, and data validity.', 'Describe in this section who will have access to records.', '11.1.9.2 STUDY RECORDS RETENTION', 'Study documents will be retained for a minimum of 7 years after the last approval of a marketing application in an', 'International Conference on Harmonization (ICH) region and until there are no pending or contemplated marketing', 'applications in an ICH region or until at least 7 years have elapsed since the formal discontinuation of clinical', 'development of the study intervention. These documents will be retained for a longer period, however, if required by', 'the IRB, FDA, or DSMB. No records will be destroyed without the written consent of the NIAMS.', '11.1.10', 'PROTOCOL DEVIATIONS', 'A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on Harmonisation', 'Good Clinical Practice (ICH GCP), or Manual of Operating Procedures (MOOP) requirements. The noncompliance may be', 'either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions', 'are to be developed by the site and implemented promptly.', 'It will be the responsibility of the site investigator to use continuous vigilance to identify and report protocol deviations.', 'Per the NIAMS reporting requirements, deviations/violations that impact participant safety will be reported to the', 'NIAMS and the DSMB Safety Officer (through KAI) within 48 hours of the PI becoming aware of the event. Protocol', '40']\n\n###\n\n", "completion": "END"}